Supernus Pharmaceuticals (SUPN) P/E Ratio
P/E Ratio as of Jul 2, 2025: 29.04
Average29.20
Median29.23
Minimum28.21
Maximum30.12
29.04
Past Month+0.15 (0.52%)
The P/E ratio for Supernus Pharmaceuticals (SUPN) is 29.04 as of Jul 2, 2025. This represents a decrease of -65.98% compared to its 12-month average P/E ratio of 85.35. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Supernus Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Supernus Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Supernus Pharmaceuticals to industry peers.
Supernus Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Supernus Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Supernus Pharmaceuticals to industry peers.
Supernus Pharmaceuticals (SUPN) P/E Ratio Insights
See Supernus Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Supernus Pharmaceuticals (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares
Supernus Pharmaceuticals (SUPN) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jul 1, 2025 | $31.82 | 28.81 |
| Jun 2, 2025 | $31.91 | 28.89 |
| May 1, 2025 | $32.45 | 24.62 |
| Apr 1, 2025 | $31.68 | 24.03 |
| Mar 3, 2025 | $31.74 | 24.08 |
| Feb 3, 2025 | $37.36 | 34.98 |
| Jan 2, 2025 | $36.43 | 34.11 |
Supernus Pharmaceuticals (SUPN) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | 29.04 | -14.21% |
| 2024 | 33.85 | -54.58% |
| 2023 | 74.53 | +32.95% |
| 2022 | 56.06 | +88.44% |
| 2021 | 29.75 | +179.61% |
| 2020 | 10.64 | — |
FAQs About Supernus Pharmaceuticals (SUPN) P/E ratio
The latest P/E ratio of Supernus Pharmaceuticals (SUPN) is 29.04, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Supernus Pharmaceuticals’s last 12-month average P/E ratio is 85.35, compared to its current P/E ratio of 29.04. This reflects a decrease of -65.98%.
Supernus Pharmaceuticals’s current P/E ratio of 29.04 is lower than its last 12-month average P/E of 85.35. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Supernus Pharmaceuticals’s average P/E ratio over the last 3 years is -2622.56. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Supernus Pharmaceuticals’s average P/E ratio over the last 5 years is -1566.56. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.